Right now, chemotherapy is the front-line treatment for metastatic colorectal cancer. Ipi/nivo and pembro are options for patients with MSI-high or MMR-deficient disease. About 10-15% of patients fall into this category. In KEYNOTE-177, pembro was given as front-line therapy head-to-head with standard mFOLFOX6 or FOLFIRI +/- bevacizumab/cetuximab. You guessed it, Merck already announced a significant improvement in progression-free survival with single agent pembro. The Betting Line: Pembrolizumab alone results in significantly better progression-free survival compared to front-line chemot for patients with dMMR/MSI-H advanced colorectal cancer. | Andre, ASCO 2020


Popular Posts